Company Profile
Arcellx Stock Price, News & Analysis
- Ticker:
- ACLX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
115.07 USD (+0.03%)
Close
Last updated: April 27, 2026
—
Market cap
Why the stock is moving
Current closing-price context is not available for ACLX.
Company overview
Business overview
Arcellx is a cell-therapy company focused on engineered therapies for cancer, especially multiple myeloma.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Arcellx sits in advanced oncology cell therapy.
Business Model Characteristics
Its value is tied to platform validation, clinical data, and the path toward commercial cell-therapy execution.
Position Within the Biotechnology Landscape
Arcellx is a high-catalyst cell-therapy name that investors watch for data readouts and platform differentiation.
Future catalysts
Arcellx's catalysts are anito-cel in multiple myeloma and any cell-therapy update that shows the platform can keep building. The market will care about durability and differentiation in a crowded myeloma field.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Arcellx (ACLX)?
Arcellx (ACLX) most recently closed at 115.07 USD, a +0.03% move versus the previous session.
What does Arcellx do?
Arcellx is a cell-therapy company focused on engineered therapies for cancer, especially multiple myeloma.
On which exchange is ACLX stock listed?
Arcellx (ACLX) is associated with NASDAQ, United States, Biopharma.
What is Arcellx?
Arcellx's catalysts are anito-cel in multiple myeloma and any cell-therapy update that shows the platform can keep building.
Which conditions is Arcellx targeting with Arcellx?
Arcellx is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does Arcellx describe recent progress with Arcellx?
Arcellx's catalysts are anito-cel in multiple myeloma and any cell-therapy update that shows the platform can keep building.
What future catalysts are investors watching for Arcellx?
Arcellx's catalysts are anito-cel in multiple myeloma and any cell-therapy update that shows the platform can keep building. The market will care about durability and differentiation in a crowded myeloma field.